Progress + Pipeline
We launched in January 2020 to tackle the next frontier of innovation: reducing the cost of medicine. Through strategic partnerships with stakeholders from across the healthcare ecosystem and cutting-edge science and technology, we aim to provide high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
Here is a summary of our major achievements so far…
- Assembled 200+ passionate and brilliant employees from across healthcare.
- Built an executive team of renowned industry veterans, all inspired by a common cause.
- Created an award-winning culture to attract and empower top experts and changemakers, earning 20+ company awards.
- Forged partnerships with leading drug discovery companies to help rapidly expand our early-stage pipeline of novel medicines, including announcements with Exscientia and AbCellera.
- Developing strategic collaborations with national and regional health plans and large integrated delivery networks and health systems to improve access to potential EQRx medicines for physicians and patients alike.
- Formed a mission advisory board consisting of world leaders from pharmaceutical R&D, research science, health economics and patient advocacy.
- Raised $800M in funding, demonstrating that the world is ready for this new approach to affordable medicine and empowering us to keep striving for what’s next.
Our growing pipeline of 10+ programs includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs. Our drug candidates span across high-cost disease areas of today and the future.
We are further expanding our pipeline through drug engineering collaborations with leading drug discovery companies including Exscientia and AbCellera.
We have disclosed several late-stage drug candidates currently in development that show promise in the treatment of a number of cancers, including lung, breast and other solid tumors:
- Aumolertinib, a third–generation EGFR inhibitor in-licensed from Hansoh Pharmaceuticals, is in development to treat EGFR-mutated NSCLC, which is already approved for second-line treatment in China and is in late-stage clinical trials in first-line treatment. Positive Phase 3 study results were presented at ASCO 2021.
- Sugemalimab, an anti-PD-L1 antibody in-licensed from CStone Pharmaceuticals, is in development to treat Stage III and IV NSCLC. Positive Phase 3 study results were previously presented in Stage IV NSCLC at ESMO Asia 2020 and positive Phase 3 study results in Stage III disease were reported in May 2021. Sugemalimab has also received Breakthrough Therapy designation from the US FDA for the treatment of adult patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).
- Lerociclib, a CDK4/6 inhibitor in-licensed from G1 Therapeutics, is in development to treat HR+/HER2- breast cancer, which represents ~70% of all breast cancers.1
- EQ176 (formerly known as CS1003; licensed through EQRx’s partnership with CStone), is an anti-PD-1 antibody which has received Orphan Drug Designation from FDA for a primary type of liver cancer.
In addition to these four late-stage drug candidates, EQRx has a portfolio of undisclosed clinical and preclinical-stage drug candidates targeting diseases areas of high-cost burden.
To help raise awareness of the impact of financial toxicity and to introduce EQRx’s mission and method for addressing it, we’ve launched the #RemakingMedicine Video Series.
Our team of world-renowned industry leaders discusses the negative clinical impact of high drug prices, explains why scientific advancement in the last decade allows for much more efficient creation of new medicines and invites all across the industry to join in creating a new model to make innovation more accessible to patients across the globe.
And we’re just getting started.
Subscribe below to stay tuned for all of the EQRx progress to come.
- Decision Resources Group (DRG). Breast Cancer Disease Landscape & Forecast Report. Available: https://decisionresourcesgroup.com/report/dlsfon0001-biopharma-breast-cancer-landscape-forecast-disease/. Accessed August 5, 2021.
50 Hampshire Street
Cambridge, MA 02139